Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4806896 | 1.00 | HRH3 (0.66) | HRH3SIGMAR1NPC1RAB9AMAOA | |
| SCHEMBL7355512 | 1.00 | HRH3 (0.66) | HRH3SIGMAR1NPC1RAB9AMAOA | |
| SCHEMBL6802109 | 0.96 | HRH3 (0.68) | HRH3SIGMAR1NPC1RAB9AMAOA | |
| SCHEMBL6798708 | 0.88 | HRH3 (0.57) | HRH3SIGMAR1 | |
| SCHEMBL7359013 | 0.84 | HRH3 (0.69) | HRH3SIGMAR1MEN1KMT2A | |
| SCHEMBL7359002 | 0.84 | HRH3 (0.69) | HRH3SIGMAR1MEN1KMT2A | |
| SCHEMBL8938233 | 0.83 | HRH3 (0.66) | HRH3SIGMAR1NPC1RAB9AMAOA | |
| Hydrochloric Acid SCHEMBL9752578 | 0.83 | HRH3 (0.67) | HRH3SIGMAR1MEN1KMT2A | |
| SCHEMBL7351513 | 0.83 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2A | |
| SCHEMBL7351505 | 0.83 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320973-B2 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| US-7320973-B2 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1403258-A1 | DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
| CN-1085209-C | 5, 11-dihydrodibenzo [ b, e ] [1,4] oxazepine * derivative and pharmaceutical composition containing the same | AJINOMOTO KK (JP) | 2002-05-22 | — | — | CN | disclosed |
| EP-0889043-B1 | 5,11-DIHYDRODIBENZ b,e] 1,4]OXAZEPINE DERIVATIVES AND DRUG COMPOSITIONS CONTAING THE DERIVATIVES | AJINOMOTO KK (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-6127361-A | FOR TREATMENT OR PREVENTION OF GASTROINTESTINAL MOVING FUNCTION DISORDERS, IRRITABLE BOWEL SYNDROME | AJINOMO CO., INC. (JP) | 2000-10-03 | — | — | US | disclosed |
| CN-1213371-A | 5,11-dihydrodibenz [b,e] [1,4] oxazepine derivatives and drug compositions containing the devivatives | AJINOMOTO KK (JP) | 1999-04-07 | — | — | CN | disclosed |
| EP-0889043-A1 | 5,11-DIHYDRODIBENZ b,e] 1,4]OXAZEPINE DERIVATIVES AND DRUG COMPOSITIONS CONTAING THE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 1999-01-07 | — | — | EP | disclosed |
| EP-0404359-B1 | Dibenzothiazepine derivatives useful as antispasmodic agents | PFIZER LTD (GB) | 1994-06-29 | — | — | EP | disclosed |
| US-5071844-A | Antispasmodic agents | PFIZER INC. (US) | 1991-12-10 | — | — | US | disclosed |
| WO-1991010648-A1 | DIPHENYLSULPHOXIMINE MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
| EP-0404359-A1 | Dibenzothiazepine derivatives useful as antispasmodic agents | Pfizer Limited (GB) | 1990-12-27 | — | — | EP | disclosed |
| CN-1047673-A | Anticonvulsants | PFIZER (US) | 1990-12-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | CYP3A4, PPARD, CYP4B1 | HRH3 518/4885SIGMAR1 998/4885NPC1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.